Nas clinical trials

Explore recruiting nas clinical trials.

Recruiting nas studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nas trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Romania, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase IIa Proof-of-Concept Study, with Dose-Titration Based on Treat-to-Target Strategy, to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Injection of Folate-based Liposomes Encapsulating Methotrexate (FBL-MTX) in Disease-modifying Antirheumatic Drugs (DMARD)-naïve Patients with Moderate-to-Severe Active Rheumatoid Arthritis and in Patients with an Inadequate Response or Intolerance to Oral MTX.

Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II clinical trial to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Open-Label Study of Safety, Pharmacokinetics and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 months old with Arginase 1 Deficiency

Portugal, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Poland, Belgium, Austria, Hungary, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Nas trials by city

Nas in Toronto Nas in Vancouver Nas in Montreal Nas in Calgary Nas in Edmonton Nas in Ottawa Nas in Winnipeg Nas in Quebec City Nas in Hamilton Nas in Kitchener Nas in London Nas in Halifax Nas in New York Nas in Los Angeles Nas in Chicago Nas in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease